Clinical Trial ResultsThe data from the Ph3 ICONIC-TOTAL study demonstrated consistent efficacy of icotrokinra in PsO, with a positive impact on the scalp PsO, which appears to be more profound than what Sotyktu showed in similar patient populations.
Market PotentialRusfertide is expected to emerge as a blockbuster in the PV market following the VERIFY data.
Regulatory ProspectsAn NDA filing is expected for both rusfertide and icotrokinra, indicating potential upcoming regulatory approvals.